Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 51 - 75 of 338 in total

Cetalkonium

Cetalkonium is a C16 alkyl benzalkonium chloride derivative with an amphipathic property which allows it to be used in different types of formulations. It is a quaternary ammonium salt that acts as an antiseptic against a variety of bacteria and fungi. Cetalkonium is approved by the FDA for its use...
Approved
Matched Salts name: … Cetalkonium bromide …

Ambenonium

Ambenonium is a cholinesterase inhibitor. It is used in the management of myasthenia gravis.
Approved

Butylscopolamine

Butylscopolamine is a peripherally acting antimuscarinic, anticholinergic agent. It is used to treat pain and discomfort caused by abdominal cramps, menstrual cramps, or other spasmodic activity in the digestive system. It is also effective at preventing bladder spasms. It is not a pain medication in the normal sense, since it...
Approved
Investigational
Vet approved
Matched Salts name: … Butylscopolamine bromide …

Lurasidone

Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.
Approved
Investigational

Ziprasidone

Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior. These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers. Luckily, several treatment options for psychotic disorders have been...
Approved

Dexbrompheniramine

Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria.
Approved

Lesinurad

Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter associated with...
Approved
Investigational

Vandetanib

Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
Approved

Bromperidol

Bromperidol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders, among others.
Approved
Investigational

Valproic acid

Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investigations into...
Approved
Investigational

Remimazolam

Remimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation during short (<30 minute) procedures. Recent trends in anesthesia-related drug development have touted the benefits of so-called "soft drugs" - these agents, such as remifentanil, are designed to be metabolically fragile and thus susceptible to rapid...
Approved
Investigational

Olanzapine

Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resembles clozapine and only differs by...
Approved
Investigational

Remoxipride

Remoxipride is an atypical antipsychotic agent that is specific for dopamine D2 receptors. It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]
Approved
Withdrawn

Nicergoline

An ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. It has been suggested to ameliorate cognitive deficits in cerebrovascular disease.
Approved
Investigational

Phloxine B

Phloxine B (commonly known simply as phloxine, also known as D&C RED NO. 28) is a color additive which is used both as an inactive ingredient to provide color to products, or as a colorant in dental disclosing tablets. These tablets allow patients to visualise areas where more brushing and...
Approved

Bromocriptine

Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as the treatment of acromegaly. Bromocriptine has been...
Approved
Investigational
Withdrawn

Budesonide

Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product...
Approved
Matched Categories: … formoterol, glycopyrronium bromide and budesonide …

Methscopolamine bromide

A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.
Approved
Matched Synonyms: … Hyoscine methyl bromide ... Methscopolamine bromide ... N-methylhyoscine bromide …
Matched Name: … Methscopolamine bromide …
Matched Iupac: … -{[(2S)-3-hydroxy-2-phenylpropanoyl]oxy}-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.0^{2,4}]nonan-9-ium bromide …
Matched Products: … Methscopolamine Bromide …

Lithium hydroxide

Used for tryptophan determinations in proteins & foods.
Approved
Withdrawn
Matched Synonyms: … Lithium hydrate ... Lithium hydroxide anhydrous …
Matched Name: … Lithium hydroxide …
Matched Iupac: … lithium(1+) hydroxide …
Matched Salts name: … Lithium hydroxide monohydrate …
Matched Categories: … Lithium Compounds …
Matched Products: … Lithium Hydroxide Monohydrate …

Anisotropine methylbromide

Anisotropine methylbromide is a quaternary ammonium compound. Its use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents. Depending on the dose, anisotropine methylbromide may reduce the motility and secretory activity of the gastrointestinal system, and the tone of the ureter and urinary...
Approved
Matched Synonyms: … Methyloctatropine bromide ... 8-Methyltropinium bromide 2-propylvalerate ... 8-Methyltropinium bromide 2-propylpentanoate …
Matched Iupac: … 8,8-dimethyl-3-[(2-propylpentanoyl)oxy]-8-azabicyclo[3.2.1]octan-8-ium bromide …

Tiotropium

Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma.[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.[A180163,L7084,L7087,L7090,L7093] Tiotropium is more specific for the subset of muscarinic receptors commonly found in the...
Approved
Matched Salts name: … Tiotropium bromide ... Tiotropium bromide monohydrate …
Matched Categories: … tiotropium bromide ... tiotropium bromide, combinations ... olodaterol and tiotropium bromide ... formoterol and tiotropium bromide …
Matched Products: … Tiotropium Bromide …

Neostigmine

A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.
Approved
Vet approved
Matched Salts name: … Neostigmine bromide …

Methylnaltrexone

Methylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms. It is also a weak CYP2D6 inhibitor. FDA approved in 2008.
Approved
Matched Salts name: … Methylnaltrexone bromide …
Matched Categories: … methylnaltrexone bromide …

Lumateperone

Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including aripiprazole, paliperidone and clozapine available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumateperone is a newly approved 2nd generation antipsychotic currently indicated for the...
Approved
Investigational

Samidorphan

Olanzapine is an effective atypical antipsychotic that, like other antipsychotics, is associated with weight gain, metabolic dysfunction, and increased risk of type II diabetes.[A235638, A235643] Samidorphan is a novel opioid antagonist structurally related to naltrexone, with a higher affinity for opioid receptors, more potent μ-opioid receptor antagonism, higher oral bioavailability,...
Approved
Investigational
Displaying drugs 51 - 75 of 338 in total